Treatment of cancer with allogeneic natural killer (NK) cell therapies has seen rapid
development, especially use against hematologic malignancies. Clinical trials of NK cell-
based adoptive transfer to treat relapsed or refractory malignancies have used peripheral
blood, umbilical cord blood and pluripotent stem cell-derived NK cells, with each approach
undergoing continued clinical development. Improving the potency of these therapies relies
on genetic modifications to improve tumor targeting and to enhance expansion and …